english.prescrire.org > Spotlight > 100 most recent > Midostaurin (Rydapt°) for some types of acute myeloid leukaemia


Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

In the February issue of Prescrire International: Midostaurin (Rydapt°) for some types of acute myeloid leukaemia

FREE DOWNLOAD In this month's sample review, Prescrire's editors give this multi-tyrosine kinase inhibitor a rating of "Offers an advantage", but warn that the drug's adverse effects are underestimated.
Full text available for free download.


  • Midostaurin (Rydapt°) has been authorised in the European Union for patients with newly diagnosed acute myeloid leukaemia who carry a FLT3 mutation.
  •  OFFERS AN ADVANTAGE  In a trial in 717 patients with acute myeloid leukaemia and a FLT3 mutation, midostaurin (a multi-tyrosine kinase inhibitor) added to induction and consolidation therapy, and then continued as maintenance monotherapy, increased the proportion of patients alive at 5 years by 8%. It was not evaluated in patients aged over 60 years, who generally have a worse prognosis. According to an incomplete assessment of its adverse effects, midostaurin mainly carries a risk of gastrointestinal disorders, elevated transaminase levels and lymphopoenia. In practice, midostaurin can be offered to patients aged less than 60 years with careful monitoring of adverse effects. It is important to report these adverse effects.

Full text available for free download.

 ©Prescrire 1 February 2019

"Midostaurin (Rydapt°) for some types of acute myeloid leukaemia" Prescrire Int 2019; 28 (201): 40. (Pdf, free).

Share Share on Facebook Share on Twitter


Partager sur Facebook Partager sur Twitter

Download the full review
Pdf, free
Prescrire's rating:
Prescrire's rating

See also:

Midostaurin (Rydapt°) in
mastocytosis. Appears
to prolong survival in
mast cell leukaemia
Prescrire Int 2019.
28 (201): 38-39.
Pdf, subscribers only